{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:45:34Z","timestamp":1790829934426,"version":"4.1.0"},"reference-count":75,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.2217\/imt.15.77","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T08:54:27Z","timestamp":1442307267000},"page":"1187-1199","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":174,"title":["Targeting B-Cell Maturation Antigen in Multiple Myeloma"],"prefix":"10.1080","volume":"7","author":[{"given":"Yu-Tzu","family":"Tai","sequence":"first","affiliation":[{"name":"Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C","family":"Anderson","sequence":"additional","affiliation":[{"name":"Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,9,15]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.200"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1517\/14796694.1.2.161"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2549"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.171"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/138945009789577936"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61188"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07064"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(04)00019-4"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2189"},{"key":"e_1_3_2_12_1","first-page":"110","volume-title":"Myeloma: Pathology, Diagnosis & Management","author":"Tai YT","year":"2014","unstructured":"Tai YT , AndersonKC. Principles of pathway directed therapy. In: Myeloma: Pathology, Diagnosis & Management. ScheySA, YongKL, MarcusR, AndersonKC (Eds).Cambridge University Press, NY, USA, 110\u2013120 (2014)."},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00924.x"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015958"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI18025"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031330"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.9.5612"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.21.12.4067-4074.2001"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0008"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0190"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-1984"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4512"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405048"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2422"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0168"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535088"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-529800"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.08.019"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4463"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0753"},{"key":"e_1_3_2_31_1","first-page":"681","article-title":"Constitutive B-Cell maturation antigen (BCMA) activation in human multiple myeloma cells promotes myeloma cell growth and survival in the bone marrow microenvironment via upregulated MCL-1 and NF\u03baB signalling","author":"Tai YT","year":"2013","unstructured":"Tai YT , AcharyaC, ZhongMYet al. Constitutive B-Cell maturation antigen (BCMA) activation in human multiple myeloma cells promotes myeloma cell growth and survival in the bone marrow microenvironment via upregulated MCL-1 and NF\u03baB signalling. ASH Annual Meeting Abstracts681 (2013).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.11.1677"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01262.x"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09241.x"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.432.432"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2014.882764"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.889681"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0695"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.1.6.10029"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.2741\/4202"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2867"},{"key":"e_1_3_2_42_1","article-title":"Indatuximab Ravtansine (BT062) in combination with lenalidomide and low dose dexamethasone in patients with relapsed and\/or refractory multiple myeloma: clinical activity in patients already exposed to lenalidomide and bortezomib","volume":"122","author":"Kelly KR","year":"2014","unstructured":"Kelly KR , Chanan-KhanA, HeffnerLTet al. Indatuximab Ravtansine (BT062) in combination with lenalidomide and low dose dexamethasone in patients with relapsed and\/or refractory multiple myeloma: clinical activity in patients already exposed to lenalidomide and bortezomib. Blood122, Abstract 4736 (2014).","journal-title":"Blood"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0204"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-364521"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0464"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2010.06.170"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M510026200"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-107292"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12243"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa3643"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281931"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2013.12.001"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.279"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0721"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2510"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/35010115"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1804"},{"issue":"11","key":"e_1_3_2_61_1","first-page":"1216","article-title":"Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells","volume":"9","author":"Gatto B.","year":"2008","unstructured":"Gatto B. Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells. Curr. Opin. Investig. Drugs9(11), 1216\u20131227 (2008).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605241"},{"key":"e_1_3_2_63_1","first-page":"2098","article-title":"A novel anti-a proliferation-inducing ligand hAPRIL.01A monoclonal antibody targets multiple myeloma cells in the bone marrow microenvironment","author":"Tai YT","year":"2014","unstructured":"Tai YT , AcharyaC, AnGet al. A novel anti-a proliferation-inducing ligand hAPRIL.01A monoclonal antibody targets multiple myeloma cells in the bone marrow microenvironment. ASH Annual Meeting Abstracts2098 (2014).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.1021415"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.5b01876"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0356-3"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.103085"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-438028"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-360255"},{"issue":"6","key":"e_1_3_2_70_1","first-page":"724","article-title":"IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers","volume":"12","author":"Alici E.","year":"2010","unstructured":"Alici E. IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers. Curr. Opin. Mol. Ther.12(6), 724\u2013733 (2010).","journal-title":"Curr. Opin. Mol. Ther."},{"key":"e_1_3_2_71_1","article-title":"Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma","author":"Flores-Montero J","year":"2015","unstructured":"Flores-Montero J , de TuteR, PaivaBet al. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin. Cytom. (2015).","journal-title":"Cytometry B Clin. Cytom."},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.1"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2206"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-029355"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0143"},{"issue":"4","key":"e_1_3_2_76_1","first-page":"1493","article-title":"AJ VDE. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies","volume":"34","author":"Azijli K","year":"2014","unstructured":"Azijli K , StellooE, PetersGJ,, AJ VDE. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies. Anticancer Res.34(4), 1493\u20131505 (2014).","journal-title":"Anticancer Res."},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31821ca6ce"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt.15.77","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T14:53:14Z","timestamp":1715957594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt.15.77"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,15]]},"references-count":75,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.2217\/imt.15.77"],"URL":"https:\/\/doi.org\/10.2217\/imt.15.77","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-09-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}